Ascletis Pharma Inc.

Ascletis Pharma Inc. is a fully integrated biotechnology company headquartered in Hangzhou, China. The company is dedicated to the research, development, production, marketing, and sale of innovative pharmaceutical products. Its mission is to develop and commercialize potential best-in-class and first-in-class therapeutics to address significant unmet medical needs globally.

Ascletis focuses on three primary therapeutic areas: metabolic diseases, viral diseases, and oncology, with additional interests in dermatology. Key marketed products include Ritonavir tablets, GANOVO®, and ASCLEVIR® for Hepatitis C. The company's pipeline features numerous drug candidates, such as ASC30 for obesity and diabetes, ASC22 for HBV and HIV functional cure, ASC10 for COVID-19 and monkeypox, ASC40 for NASH, acne, and glioblastoma, and ASC61 for advanced solid tumors. Ascletis leverages proprietary technologies including Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT) to advance its drug discovery efforts.

Led by Founder, Chairman, and CEO Dr. Jinzi Jason Wu, Ascletis is an R&D-driven biotech listed on the Hong Kong Stock Exchange. Recent notable developments include the completion of enrollment in a U.S. Phase II study for ASC30 (oral GLP-1R agonist) for diabetes in April 2026, with topline data anticipated in the third quarter of 2026. In March 2026, the company announced positive topline results from a U.S. Phase II study for its ultra-long-acting subcutaneous depot formulations of ASC30 for obesity. Additionally, in December 2025, China's National Medical Products Administration accepted the New Drug Application for denifanstat (ASC40), a first-in-class FASN inhibitor for acne treatment.

Latest updates

Ascletis Presents Obesity Drug Data, Highlights Oral Amylin Agonist

Event summary

  • Ascletis will present data on multiple metabolic disease programs at the American Diabetes Association's 2026 Scientific Sessions, June 5–8 in New Orleans.
  • A late-breaking poster will focus on ASC39, a preclinical oral small molecule amylin receptor agonist for obesity.
  • Phase II data for ASC30, a GLP-1 agonist, showed a 7.7% placebo-adjusted weight loss with improved GI tolerability.
  • ASC37, a triple agonist peptide, demonstrated a 4.2% oral bioavailability in nonhuman primate studies.
  • Ascletis utilizes AISBDD, ULAP, and POTENT technologies in its drug development.

The big picture

The obesity treatment market is experiencing rapid innovation with a focus on novel mechanisms and oral delivery. Ascletis’ portfolio, encompassing GLP-1 agonists, amylin receptor agonists, and triple agonists, positions it to capitalize on this growth, but the company faces intense competition from established players and emerging therapies. The success of ASC39, particularly its oral delivery, could be a significant differentiator, but the low bioavailability of ASC37 raises concerns about the broader applicability of Ascletis’ peptide transport technology.

What we're watching

Clinical Validation
The late-breaking ASC39 data will be crucial in assessing the viability of Ascletis’ oral amylin receptor agonist approach, which faces challenges in achieving sufficient efficacy and bioavailability.
Regulatory Pathway
Given the competitive landscape in obesity treatment, the FDA's acceptance and timeline for ASC30’s potential approval will significantly impact Ascletis’ market positioning.
Bioavailability Hurdles
The low oral bioavailability (4.2%) of ASC37 highlights a significant hurdle for peptide-based therapies, and Ascletis’ ability to overcome this will determine its long-term prospects.

Ascletis Advances Obesity Drug Candidate with Novel GLP-1/Amylin Combination

Event summary

  • Ascletis Pharma has selected ASC30_39 FDC, a fixed-dose combination of GLP-1R agonist ASC30 and amylin receptor agonist ASC39, for clinical development targeting obesity.
  • Preclinical dog studies indicate ASC30_39 FDC exhibits comparable pharmacokinetics to its monotherapies, with excellent oral bioavailability and a 12-hour half-life.
  • ASC30, a Phase III-ready GLP-1R agonist, demonstrates a favorable GI profile, showing half the vomiting rate compared to orforglipron in non-head-to-head studies.
  • Ascletis plans to submit an Investigational New Drug (IND) application to the FDA for ASC30_39 FDC in Q3 2026.
  • The company claims ASC30_39 FDC represents the first publicly announced co-formulation of an oral GLP-1 and oral amylin.

The big picture

The obesity treatment market is experiencing rapid growth, driven by increasing prevalence and the emergence of effective therapies like GLP-1 receptor agonists. Ascletis’s approach of combining a GLP-1 agonist with an amylin agonist represents a novel strategy to potentially enhance efficacy and address limitations of existing treatments. However, the combination also introduces complexity in terms of safety and regulatory approval, and the company faces significant competition from established players and emerging therapies.

What we're watching

Clinical Trial Design
The success of ASC30_39 FDC will heavily depend on the design and execution of Phase 1 and subsequent clinical trials, particularly given the combination of two distinct mechanisms of action and the need to demonstrate synergistic efficacy and safety.
Regulatory Pathway
The FDA’s review of the IND submission and subsequent clinical trial data will be crucial; the novelty of the combination therapy could introduce unforeseen regulatory hurdles or require extensive safety data.
Competitive Landscape
The obesity treatment market is increasingly crowded, and Ascletis will need to demonstrate a clear advantage over existing and emerging therapies, including both GLP-1 receptor agonists and amylin mimetics, to achieve commercial success.

Ascletis Advances Oral Amylin Agonist ASC39, Mimicking Eli Lilly's Approach

Event summary

  • Ascletis Pharma has selected ASC39, a novel oral small molecule amylin receptor agonist, as its clinical development candidate for obesity treatment.
  • Preclinical data indicate ASC39 demonstrates comparable selectivity and efficacy to eloralintide, with similar EC50 values for hAMY1R and comparable weight loss in DIO rat models.
  • Ascletis plans to submit an Investigational New Drug (IND) application for ASC39 oral tablets to the U.S. FDA in Q3 2026.
  • ASC39 was developed using Ascletis’ AI-assisted Structure-Based Drug Discovery (AISBDD) technology.

The big picture

Ascletis is pursuing a strategy of oral amylin receptor agonists, mirroring Eli Lilly’s approach with eloralintide, to address the growing market for obesity treatments. The company’s use of AI-driven drug discovery suggests a focus on efficiency and potentially novel chemical scaffolds. The success of ASC39 will hinge on demonstrating a compelling clinical profile and navigating a crowded therapeutic space.

What we're watching

Regulatory Risk
The FDA’s review of Ascletis’ IND submission for ASC39 will be critical, and any delays or requests for additional data could impact the program's timeline and cost.
Clinical Efficacy
While preclinical data are promising, the true test will be ASC39’s efficacy and safety in human clinical trials, which will determine its potential to compete with existing and emerging obesity treatments.
Commercialization
Ascletis’ ability to successfully commercialize ASC39, particularly given the competitive landscape in obesity treatment, will depend on demonstrating a clear advantage over existing therapies and securing favorable reimbursement.

Ascletis Phase II Data Show Promise for Quarterly Obesity Treatment

Event summary

  • Ascletis’ ASC30 subcutaneous depot formulation achieved a 7.5% placebo-adjusted mean weight loss at week 16 in a U.S. Phase II trial.
  • Data suggest ASC30 may enable quarterly dosing for maintenance therapy, maintaining weight loss for four months after the last dose.
  • Formulation A1 demonstrated therapeutic drug exposures and a favorable safety profile consistent with existing GLP-1 drugs.
  • The trial, conducted in 65 participants, evaluated two formulations (A1 and A2), with A1 showing superior results.

The big picture

Ascletis’ Phase II results represent a significant step in the race to develop more convenient and effective obesity treatments. The potential for quarterly dosing addresses a key patient compliance challenge in the GLP-1 market, which is currently dominated by weekly injections. However, the company faces the challenge of demonstrating sustained efficacy and safety in larger, Phase III trials, and competing with established players with significant resources.

What we're watching

Regulatory Pathway
The success of ASC30 hinges on navigating FDA approval for a novel, long-acting GLP-1 therapy, which could face scrutiny regarding efficacy and safety over extended periods.
Competitive Landscape
Given the crowded GLP-1 market, Ascletis will need to demonstrate a clear advantage over existing and emerging therapies, particularly in terms of dosing frequency and patient adherence.
Formulation Scalability
While Formulation A1 showed promise, Ascletis must now focus on scaling up production and ensuring consistent quality for both A1 and A2, as well as addressing why A2 failed to achieve therapeutic drug exposures.

Ascletis Advances Oral Amylin Agonist with Promising Early Data

Event summary

  • Ascletis Pharma selected ASC36, an oral amylin receptor peptide agonist, for clinical development, utilizing its proprietary POTENT technology.
  • ASC36 demonstrated up to 13.2% body weight reduction and significant food intake reduction in non-human primate (NHP) studies with once-daily dosing.
  • In a rat model, ASC36 showed superior weight loss compared to eloralintide and petrelintide.
  • Ascletis anticipates submitting an Investigational New Drug Application (IND) to the FDA in Q2 2026.
  • ASC36's oral bioavailability of 6-8% and long elimination half-life (116-167 hours) suggest potential for lower doses and scalability advantages.

The big picture

The obesity treatment market is experiencing rapid innovation, with oral peptide agonists representing a significant advancement over injectable options. Ascletis' POTENT technology, if validated in clinical trials, could provide a competitive edge by enabling convenient oral delivery and potentially reducing manufacturing costs. The success of ASC36 will hinge on demonstrating superior efficacy and safety compared to existing and emerging therapies in a crowded market.

What we're watching

Clinical Trial Design
The clinical trial design for ASC36 will be critical in demonstrating efficacy and safety compared to existing therapies, particularly given the relatively low oral bioavailability.
Regulatory Pathway
The FDA's response to the IND submission and subsequent review process will dictate the timeline for potential market entry and influence investor sentiment.
Competitive Landscape
Ascletis will need to clearly differentiate ASC36 from emerging oral GLP-1R agonists and other amylin-targeting therapies to secure market share.

Ascletis Advances Acne Treatment with Positive Phase III Safety Data

Event summary

  • Ascletis announced positive topline results from a Phase III open-label study of Denifanstat (ASC40) for acne, evaluating long-term safety in 240 patients.
  • The study, conducted in China, showed a favorable safety and tolerability profile with no grade 3/4 adverse events or serious adverse events related to Denifanstat.
  • Previously, a placebo-controlled Phase III trial in June 2025 demonstrated efficacy, and a New Drug Application (NDA) for Denifanstat was accepted by the China National Medical Products Administration.
  • Denifanstat (ASC40) inhibits sebum production and inflammation, targeting a key underlying cause of acne, differentiating it from many existing treatments.

The big picture

Ascletis's Denifanstat represents a potential first-in-class treatment for acne, addressing a significant unmet need by targeting the underlying cause of sebum overproduction. The positive safety data, combined with previously reported efficacy, strengthens the likelihood of regulatory approval in China, a market with substantial growth potential. However, the success of Denifanstat will depend on navigating China's regulatory environment and effectively competing against established treatments.

What we're watching

Regulatory Approval
The speed of NDA approval by the China National Medical Products Administration will be a key indicator of Ascletis's market entry timeline and potential revenue generation.
Commercial Execution
Ascletis's ability to effectively market and distribute Denifanstat within China will determine the drug's ultimate commercial success, given the competitive landscape of acne treatments.
Sagimet Relationship
The ongoing relationship with Sagimet Biosciences, particularly concerning potential future licensing or collaboration opportunities, warrants monitoring.

Ascletis Advances Novel Triple Agonist with Extended Half-Life

Event summary

  • Ascletis Pharma selected ASC37, a GLP-1R/GIPR/GCGR triple peptide agonist, for clinical development.
  • NHP studies showed ASC37’s half-life was 7x longer than retatrutide’s, supporting once-monthly subcutaneous dosing.
  • ASC37 demonstrates 5- to 4-fold greater in vitro potency compared to retatrutide across GLP-1R, GIPR, and GCGR.
  • An IND submission to the FDA is anticipated in Q2 2026, with Phase I trials expected to begin in H2 2026.

The big picture

Ascletis is leveraging AI and proprietary technology to compete in the rapidly expanding obesity treatment market, currently dominated by Novo Nordisk and Eli Lilly. The extended half-life and enhanced potency of ASC37, if validated in clinical trials, could offer a differentiated profile and potentially capture significant market share. The company’s strategy of combining ASC37 with ASC36 highlights a broader approach to metabolic disease management.

What we're watching

Clinical Efficacy
The success of ASC37 will hinge on demonstrating comparable or superior clinical efficacy to existing GLP-1R agonists and dual agonists in Phase I and subsequent trials, particularly given the crowded market.
Regulatory Pathway
The FDA’s review of the IND submission and subsequent clinical trial data will be critical, as the novel triple agonist mechanism may require additional scrutiny and data to support approval.
Manufacturing Scale
Ascletis’ ability to scale up production of ASC37’s SQ depot formulations to meet potential demand will be a key factor in its commercial success, given the complexity of peptide manufacturing.
CID: 1329